| 0.4 -0.06 (-13.04%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Vallon Pharmaceuticals, Inc. is a biopharmaceutical enterprise focused on inventing and bringing to market new medicines for central nervous system disorders, with a particular emphasis on formulations designed to deter misuse. Its foremost investigational drug candidate, ADAIR, is an orally administered, abuse-resistant version of immediate-release dextroamphetamine, developed for the management of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also progressing ADMIR, which is another abuse-deterrent methylphenidate formulation targeting the treatment of ADHD. Founded in 2018, Vallon Pharmaceuticals, Inc. is headquartered in Philadelphia, Pennsylvania.
Fri, 04 Sep 2026
Vallon Pharmaceuticals Inc. (VLON) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Sun, 27 Nov 2022
Ofir Levi Net Worth (2026) - GuruFocus
Sun, 24 Apr 2022
U.S stock market gainers for the week - Nairametrics
Wed, 10 Feb 2021
Vallon Pharmaceuticals out of the gate with region's first life sciences IPO of 2021 - The Business Journals
Tue, 09 Feb 2021
VLON IPO News - Abuse-deterrent drug developer Vallon Pharmaceuticals prices $18 million IPO at $8 low end - Renaissance Capital
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|